The Children's Hospital of Philadelphia

Ignyta, Inc.

Garrett M Brodeur

Ivan Alferiev

Michael Chorny

Zachary Dolph Hornby

Gang Li

David Wesley Anderson

Radhika Iyer

Akira Nakagawara

Peter S White

Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.

Polymer-based macromolecular prodrugs

A co-drug according to Formula (I) or Formula (II) is provided,R&#x2014;X&#x2014;NH&#x2014;CO&#x2014;CO&#x2014;OR&#x2003;&#x2003;(I)R&#x2014;X&#x2014;CO&#x2014;O&#x2014;CH&#x2014;CO&#x2014;OR&#x2003;&#x2003;(II)wherein R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety; X is a direct bond or a linking group; and ORis the residue of an anticancer or antirestenotic agent bearing at least one hydroxyl group by which the CO&#x2014;ORester linkage is formed. Nanoparticles that include the abovementioned co-drug are also provided, as well as a method of treating a cancer patient that includes administering an effective amount of the co-drug or nanoparticles.

Cleavable esters for nanocarrier-based cancer therapy

Disclosed are methods of treating neuroblastoma in a cancer patient by administration of a Trk inhibitor in combination with one more chemotherapeutic agents. Also disclosed are pharmaceutical compositions comprising a Trk inhibitor and one or more chemotherapeutic agents.

Combinations for the treatment of neuroblastoma

Nucleic acid sequences encoding chromodomain helicase DNA-binding (CHD) proteins, CHD proteins, and antibodies thereto and methods of use thereof are disclosed.

CHD5 encoding nucleic acids, polypeptides, antibodies and methods of use thereof

The amino acid sequence of the full length version of the human neurotrophic factor receptor TRK B and a nucleotide sequence encoding it are disclosed. Transformed host cells and transgenic animals containing nucleic acid molecules encoding full length human TRK-B are disclosed. Probes, primers and antisense molecules identical and complementary to the nucleotide sequence that encodes full length human TRK-B, particularly the intracellular portion of the receptor are disclosed. Monoclonal antibodies that bind to the full length human TRK-B protein are disclosed. Methods of using and kits which include probes, primers, antisense molecules and monoclonal antibodies are disclosed.

Growing community of inventors

Wynnewood, PA, United States of America

Garrett M Brodeur